NYSE:PFE

Pfizer Inc (PFE)

25.76
+0.42 (1.64%)
as of Jun 4, 2026, 2:38:43 pm Market Open.
579 watching
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY ON WEAKNESS
Good long term track record. Good management. Would like at a lower level.
BUY
Likes the drug sector.
BUY
Sector has been hit hard. At a good level. Prefers Pfizer over Merck.
DON'T BUY
DON'T BUY
Maney that went in as a defensive move is now leaving. Valuation in the sector got too high.
BUY
Excellent company. Should meet their growth potential this year. Great product lines.
WEAK BUY
Company has been doing well. Revenues growing @ 10%, earnings @ 20%. Trading at 19 X. Great long term.
DON'T BUY
Expensive.
TOP PICK
(Was a top pick on Mar 23 no change) A fan of pharmaceuticals and thinks this is the best. Goor R&D and sales.
DON'T BUY
Great com;pany. Valuation is too high.
STRONG BUY
Great product line/sales force. Good price.
DON'T BUY
Has a good pipeline. Should improve towards the end of the year.
DON'T BUY
Great pipeline of products, but has trouble breaking through the $44 level.
DON'T BUY
Very expensive now. 8/10 X Book. Has some potential, but caution.
DON'T BUY
Trading at high multiples.
Showing 811 to 825 of 883 entries